14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SLXN vs GCL: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, GCL Global Holdings Ltd (GCL) is the stronger overall head-to-head candidate over Silexion Therapeutics Corp (SLXN) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). SLXN carries a Unified Composite Score of 23.9/100 (STRONG SELL) at $1.76 (N/M Forward P/E, 0.0% operating margin), whereas GCL carries 31.6/100 (SELL) at $1.16 (N/M Forward P/E, -5.5% operating margin).
Defensive Composite Rating Caution: Although GCL compares more favorably head-to-head, both SLXN (23.9/100 STRONG SELL) and GCL (31.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: SLXN is currently in a Breakdown options structure phase (RSI 63.5); meanwhile GCL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 70.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SLXN vs GCL. Trailing 12-month operating profitability (SLXN 0.0% vs GCL -5.5%) and valuation multiples (SLXN N/M vs GCL N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Electronic Gaming & Multimedia value chain with $153.0M market capitalization and -5.5% operating margin.
OpEx & R&D Reinvestment15.8% of Rev ($38M)
90D Engineering Disclosures0 Published
Investor FAQ SLXN vs GCL Key Questions & Quantitative Answers
As of Nov 16, 2026, GCL Global Holdings Ltd (GCL) is the stronger overall head-to-head candidate over Silexion Therapeutics Corp (SLXN) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). SLXN carries a Unified Composite Score of 23.9/100 (STRONG SELL) at $1.76 (N/M Forward P/E, 0.0% operating margin), whereas GCL carries 31.6/100 (SELL) at $1.16 (N/M Forward P/E, -5.5% operating margin). Defensive Composite Rating Caution: Although GCL compares more favorably head-to-head, both SLXN (23.9/100 STRONG SELL) and GCL (31.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: SLXN is currently in a Breakdown options structure phase (RSI 63.5); meanwhile GCL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 70.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
GCL leads the Growth & Scale pillar: SLXN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with GCL at +53.8% YoY revenue growth and N/A YoY earnings growth on $239M TTM revenue (10.3% gross margin, -5.5% operating margin). On trailing 12-month operating scale, SLXN generates N/A in USD-normalized revenue versus $239M for GCL. In operating R&D and SG&A reinvestment, SLXN deploys N/A (0 90-day corporate R&D disclosures) versus 15.8% of Rev ($38M) (0 disclosures) for GCL.
GCL screens cheaper on headline valuation multiples. SLXN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas GCL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.6x EV/Revenue (-4.9% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SLXN (-897.5% ROE) versus GCL (-67.3% ROE) capital efficiency.
In options market volatility and institutional positioning, SLXN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (28.94β · 9931% Vol realized risk). By comparison, GCL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.52β · 75% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.